Alzheimer’s Drug Development: Not An Easy Path To Pursue
Anavex Life Sciences new U.S. Patent ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders
Anavex Life Sciences to Present at H.C. Wainwright 24th Annual Global Investment Conference 2022
Anavex Reports Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation in AD
